Equillium, Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. The filing was signed March 26, 2020. It also includes unaudited quarterly results, including fourth-quarter 2019. Equillium is a clinical-stage biotechnology company developing itolizumab (EQ001); it had no products approved for sale and generated no revenue.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $17.6 million | $4.9 million |
| General and administrative expense | $9.1 million | $3.7 million |
| Total operating expenses / operating loss | $26.7 million | $8.6 million |
| Net loss | $25.6 million | $13.3 million |
| Net loss per share, basic and diluted | $1.47 | $1.09 |
| Cash used in operating activities | $22.9 million | $7.5 million |
| Cash, cash equivalents and short-term investments at year-end | $53.1 million | $65.9 million |
| Long-term notes payable at year-end | $9.7 million | None |
At December 31, 2019, current assets were $55.4 million and current liabilities were $3.9 million. Stockholders’ equity was $41.8 million, and accumulated deficit was $41.1 million. The filing does not report meaningful product margins because the company had no product revenue.
Fourth-quarter 2019 operating expenses were $7.6 million and net loss was $7.6 million, or $0.44 per share, compared with fourth-quarter 2018 operating expenses of $4.2 million and net loss of $5.0 million, or $0.31 per share.
Changes versus the prior year
- Net loss increased to $25.6 million from $13.3 million, principally as operating expenses rose with clinical development and company growth.
- R&D expense increased $12.7 million, primarily from higher clinical development activity, personnel and consulting, preclinical work, and related overhead.
- G&A expense increased $5.4 million, including higher personnel and consulting costs and public-company, legal and audit expenses.
- Operating cash use increased to $22.9 million from $7.5 million. Cash and investments declined by $12.8 million to $53.1 million.
- Interest expense fell to $0.3 million from $2.6 million, largely because convertible notes had converted to equity in the 2018 IPO. Interest income rose to $1.4 million from $0.3 million as average investment balances were higher.
Business developments, outlook and risks
- During 2019, Equillium initiated Phase 1b/2 development of itolizumab for acute graft-versus-host disease (aGVHD), Phase 1b asthma testing, and Phase 1b lupus nephritis testing. FDA granted Fast Track designation for aGVHD and lupus nephritis, and Orphan Drug designations for aGVHD prevention and treatment.
- In March 2020, the company paused enrollment in the asthma and lupus nephritis trials because of COVID-19, citing patient and caregiver safety rather than observed drug safety issues. Enrollment in the aGVHD trial continued. Management expected aGVHD Phase 1b topline data in the second half of 2020; this is a forward-looking expectation, not a reported result.
- Management stated that year-end cash, cash equivalents and short-term investments were expected to fund currently planned operations for at least 12 months from the filing date. The company warned that it would need substantial additional funding to complete development and potential commercialization; financing may not be available on acceptable terms.
- In September 2019, Equillium borrowed $10 million under a loan facility of up to $20 million. An additional $5 million tranche depended on positive topline data in either aGVHD or asthma, and a further $5 million on positive data in both, subject to board confirmation and timing conditions. The loan is secured by substantially all assets other than intellectual property, subject to specified proceeds-related rights; interest is at the greater of 8.25% or prime plus 3%, and the agreement contains restrictive covenants. The company reported covenant compliance at year-end.
- The November 2019 at-the-market equity program authorized up to $8.45 million of share sales; 18,250 shares had been sold by year-end for gross proceeds of approximately $0.1 million. The company also reported $0.8 million of net ATM proceeds from post-year-end sales.
- Equillium depends on Biocon for itolizumab supply and licenses rights for the United States, Canada, Australia and New Zealand. The license carries up to $30 million in regulatory milestones, up to $565 million in sales milestones, royalties, and development and funding obligations. Biocon markets the drug in India as ALZUMAb; it was not approved or marketed elsewhere at the filing date.
- Key risks include clinical-trial failure or delay, patient enrollment, uncertain drug safety and efficacy, reliance on a single product candidate and third-party manufacturer, financing needs, competition, intellectual-property and license risks, and possible disruption from COVID-19. Indian export restrictions could also affect supply. OFAC had determined that a general license authorized clinical trials of itolizumab, but changes to that authorization could affect development.
- The company reported no litigation at year-end and no off-balance-sheet arrangements. The auditor issued an unqualified opinion on the consolidated financial statements; management reported effective disclosure controls and internal control over financial reporting. The auditor was not engaged to opine on internal-control effectiveness.
Most important facts for investors to verify
- Trial enrollment status, timing and results for aGVHD, asthma and lupus nephritis, including the effect of COVID-19 disruptions.
- Current cash runway and subsequent financing, including ATM share sales, debt draws, interest costs and covenant compliance.
- Biocon supply capacity and the status of any export restrictions, as well as the company’s ability to meet license diligence and milestone obligations.
- Whether safety findings from prior ALZUMAb studies and the healthy-volunteer itolizumab study are applicable to the company’s trials and formulations.
- Actual costs, timing and regulatory requirements for advancing the clinical programs; approval designations do not assure approval or commercial success.
- Potential dilution from outstanding options and warrants, future equity issuance, and the terms of any additional financing.